Oncology Drugs Industry Research Report 2023
This report aims to provide a comprehensive presentation of the global market for Oncology Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Drugs.
The Oncology Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Oncology Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Global markets are presented by Oncology Drugs type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Oncology Drugs are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Oncology Drugs segment by Type
This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Oncology Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Oncology Drugs market.
Oncology Drugs Segment by Application
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Oncology Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Oncology Drugs industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Drugs.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oncology Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
The Oncology Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Oncology Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Roche
- Celgene
- Novartis
- Bristol-Myers Squibb
- Johnson & Johnson
- Merck & Co.
- AstraZeneca
- Pfizer
- Amgen
- Eli Lilly
- AbbVie
- Takeda
- Astellas
- Ipsen
- Sanofi
- Bayer
- Biogen Idec
- Teva
- Otsuka
- Eisai
- Merck KGaA
- Gilead Sciences
Global markets are presented by Oncology Drugs type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Oncology Drugs are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Oncology Drugs segment by Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy
- Others
This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Oncology Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Oncology Drugs market.
Oncology Drugs Segment by Application
- Blood Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Respiratory or Lung Cancer
- Others
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Oncology Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Oncology Drugs industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Drugs.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oncology Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Oncology Drugs by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
2.3 Oncology Drugs by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Blood Cancer
2.3.3 Breast Cancer
2.3.4 Gastrointestinal Cancer
2.3.5 Prostate Cancer
2.3.6 Respiratory or Lung Cancer
2.3.7 Others
2.4 Assumptions and Limitations
3 ONCOLOGY DRUGS BREAKDOWN DATA BY TYPE
3.1 Global Oncology Drugs Historic Market Size by Type (2018-2023)
3.2 Global Oncology Drugs Forecasted Market Size by Type (2023-2028)
4 ONCOLOGY DRUGS BREAKDOWN DATA BY APPLICATION
4.1 Global Oncology Drugs Historic Market Size by Application (2018-2023)
4.2 Global Oncology Drugs Forecasted Market Size by Application (2018-2023)
5 GLOBAL GROWTH TRENDS
5.1 Global Oncology Drugs Market Perspective (2018-2029)
5.2 Global Oncology Drugs Growth Trends by Region
5.2.1 Global Oncology Drugs Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Oncology Drugs Historic Market Size by Region (2018-2023)
5.2.3 Oncology Drugs Forecasted Market Size by Region (2024-2029)
5.3 Oncology Drugs Market Dynamics
5.3.1 Oncology Drugs Industry Trends
5.3.2 Oncology Drugs Market Drivers
5.3.3 Oncology Drugs Market Challenges
5.3.4 Oncology Drugs Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Oncology Drugs Players by Revenue
6.1.1 Global Top Oncology Drugs Players by Revenue (2018-2023)
6.1.2 Global Oncology Drugs Revenue Market Share by Players (2018-2023)
6.2 Global Oncology Drugs Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Oncology Drugs Head office and Area Served
6.4 Global Oncology Drugs Players, Product Type & Application
6.5 Global Oncology Drugs Players, Date of Enter into This Industry
6.6 Global Oncology Drugs Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Oncology Drugs Market Size (2018-2029)
7.2 North America Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Oncology Drugs Market Size by Country (2018-2023)
7.4 North America Oncology Drugs Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Oncology Drugs Market Size (2018-2029)
8.2 Europe Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Oncology Drugs Market Size by Country (2018-2023)
8.4 Europe Oncology Drugs Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Oncology Drugs Market Size (2018-2029)
9.2 Asia-Pacific Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Oncology Drugs Market Size by Country (2018-2023)
9.4 Asia-Pacific Oncology Drugs Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 LATIN AMERICA
10.1 Latin America Oncology Drugs Market Size (2018-2029)
10.2 Latin America Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Oncology Drugs Market Size by Country (2018-2023)
10.4 Latin America Oncology Drugs Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Oncology Drugs Market Size (2018-2029)
11.2 Middle East & Africa Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Oncology Drugs Market Size by Country (2018-2023)
11.4 Middle East & Africa Oncology Drugs Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 PLAYERS PROFILED
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Oncology Drugs Introduction
11.1.4 Roche Revenue in Oncology Drugs Business (2017-2022)
11.1.5 Roche Recent Development
11.2 Celgene
11.2.1 Celgene Company Detail
11.2.2 Celgene Business Overview
11.2.3 Celgene Oncology Drugs Introduction
11.2.4 Celgene Revenue in Oncology Drugs Business (2017-2022)
11.2.5 Celgene Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Oncology Drugs Introduction
11.3.4 Novartis Revenue in Oncology Drugs Business (2017-2022)
11.3.5 Novartis Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Oncology Drugs Introduction
11.4.4 Bristol-Myers Squibb Revenue in Oncology Drugs Business (2017-2022)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Oncology Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Oncology Drugs Business (2017-2022)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck & Co.
11.6.1 Merck & Co. Company Detail
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Oncology Drugs Introduction
11.6.4 Merck & Co. Revenue in Oncology Drugs Business (2017-2022)
11.6.5 Merck & Co. Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Oncology Drugs Introduction
11.7.4 AstraZeneca Revenue in Oncology Drugs Business (2017-2022)
11.7.5 AstraZeneca Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Oncology Drugs Introduction
11.8.4 Pfizer Revenue in Oncology Drugs Business (2017-2022)
11.8.5 Pfizer Recent Development
11.9 Amgen
11.9.1 Amgen Company Detail
11.9.2 Amgen Business Overview
11.9.3 Amgen Oncology Drugs Introduction
11.9.4 Amgen Revenue in Oncology Drugs Business (2017-2022)
11.9.5 Amgen Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Detail
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Oncology Drugs Introduction
11.10.4 Eli Lilly Revenue in Oncology Drugs Business (2017-2022)
11.10.5 Eli Lilly Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Detail
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Oncology Drugs Introduction
11.11.4 AbbVie Revenue in Oncology Drugs Business (2017-2022)
11.11.5 AbbVie Recent Development
11.12 Takeda
11.12.1 Takeda Company Detail
11.12.2 Takeda Business Overview
11.12.3 Takeda Oncology Drugs Introduction
11.12.4 Takeda Revenue in Oncology Drugs Business (2017-2022)
11.12.5 Takeda Recent Development
11.13 Astellas
11.13.1 Astellas Company Detail
11.13.2 Astellas Business Overview
11.13.3 Astellas Oncology Drugs Introduction
11.13.4 Astellas Revenue in Oncology Drugs Business (2017-2022)
11.13.5 Astellas Recent Development
11.14 Ipsen
11.14.1 Ipsen Company Detail
11.14.2 Ipsen Business Overview
11.14.3 Ipsen Oncology Drugs Introduction
11.14.4 Ipsen Revenue in Oncology Drugs Business (2017-2022)
11.14.5 Ipsen Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Detail
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Oncology Drugs Introduction
11.15.4 Sanofi Revenue in Oncology Drugs Business (2017-2022)
11.15.5 Sanofi Recent Development
11.16 Bayer
11.16.1 Bayer Company Detail
11.16.2 Bayer Business Overview
11.16.3 Bayer Oncology Drugs Introduction
11.16.4 Bayer Revenue in Oncology Drugs Business (2017-2022)
11.16.5 Bayer Recent Development
11.17 Biogen Idec
11.17.1 Biogen Idec Company Detail
11.17.2 Biogen Idec Business Overview
11.17.3 Biogen Idec Oncology Drugs Introduction
11.17.4 Biogen Idec Revenue in Oncology Drugs Business (2017-2022)
11.17.5 Biogen Idec Recent Development
11.18 Teva
11.18.1 Teva Company Detail
11.18.2 Teva Business Overview
11.18.3 Teva Oncology Drugs Introduction
11.18.4 Teva Revenue in Oncology Drugs Business (2017-2022)
11.18.5 Teva Recent Development
11.19 Otsuka
11.19.1 Otsuka Company Detail
11.19.2 Otsuka Business Overview
11.19.3 Otsuka Oncology Drugs Introduction
11.19.4 Otsuka Revenue in Oncology Drugs Business (2017-2022)
11.19.5 Otsuka Recent Development
11.20 Eisai
11.20.1 Eisai Company Detail
11.20.2 Eisai Business Overview
11.20.3 Eisai Oncology Drugs Introduction
11.20.4 Eisai Revenue in Oncology Drugs Business (2017-2022)
11.20.5 Eisai Recent Development
11.21 Merck KGaA
11.21.1 Merck KGaA Company Detail
11.21.2 Merck KGaA Business Overview
11.21.3 Merck KGaA Oncology Drugs Introduction
11.21.4 Merck KGaA Revenue in Oncology Drugs Business (2017-2022)
11.21.5 Merck KGaA Recent Development
11.22 Gilead Sciences
11.22.1 Gilead Sciences Company Detail
11.22.2 Gilead Sciences Business Overview
11.22.3 Gilead Sciences Oncology Drugs Introduction
11.22.4 Gilead Sciences Revenue in Oncology Drugs Business (2017-2022)
11.22.5 Gilead Sciences Recent Development
13 REPORT CONCLUSION
14 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Oncology Drugs by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
2.3 Oncology Drugs by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Blood Cancer
2.3.3 Breast Cancer
2.3.4 Gastrointestinal Cancer
2.3.5 Prostate Cancer
2.3.6 Respiratory or Lung Cancer
2.3.7 Others
2.4 Assumptions and Limitations
3 ONCOLOGY DRUGS BREAKDOWN DATA BY TYPE
3.1 Global Oncology Drugs Historic Market Size by Type (2018-2023)
3.2 Global Oncology Drugs Forecasted Market Size by Type (2023-2028)
4 ONCOLOGY DRUGS BREAKDOWN DATA BY APPLICATION
4.1 Global Oncology Drugs Historic Market Size by Application (2018-2023)
4.2 Global Oncology Drugs Forecasted Market Size by Application (2018-2023)
5 GLOBAL GROWTH TRENDS
5.1 Global Oncology Drugs Market Perspective (2018-2029)
5.2 Global Oncology Drugs Growth Trends by Region
5.2.1 Global Oncology Drugs Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Oncology Drugs Historic Market Size by Region (2018-2023)
5.2.3 Oncology Drugs Forecasted Market Size by Region (2024-2029)
5.3 Oncology Drugs Market Dynamics
5.3.1 Oncology Drugs Industry Trends
5.3.2 Oncology Drugs Market Drivers
5.3.3 Oncology Drugs Market Challenges
5.3.4 Oncology Drugs Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Oncology Drugs Players by Revenue
6.1.1 Global Top Oncology Drugs Players by Revenue (2018-2023)
6.1.2 Global Oncology Drugs Revenue Market Share by Players (2018-2023)
6.2 Global Oncology Drugs Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Oncology Drugs Head office and Area Served
6.4 Global Oncology Drugs Players, Product Type & Application
6.5 Global Oncology Drugs Players, Date of Enter into This Industry
6.6 Global Oncology Drugs Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Oncology Drugs Market Size (2018-2029)
7.2 North America Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Oncology Drugs Market Size by Country (2018-2023)
7.4 North America Oncology Drugs Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Oncology Drugs Market Size (2018-2029)
8.2 Europe Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Oncology Drugs Market Size by Country (2018-2023)
8.4 Europe Oncology Drugs Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Oncology Drugs Market Size (2018-2029)
9.2 Asia-Pacific Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Oncology Drugs Market Size by Country (2018-2023)
9.4 Asia-Pacific Oncology Drugs Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 LATIN AMERICA
10.1 Latin America Oncology Drugs Market Size (2018-2029)
10.2 Latin America Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Oncology Drugs Market Size by Country (2018-2023)
10.4 Latin America Oncology Drugs Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Oncology Drugs Market Size (2018-2029)
11.2 Middle East & Africa Oncology Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Oncology Drugs Market Size by Country (2018-2023)
11.4 Middle East & Africa Oncology Drugs Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 PLAYERS PROFILED
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Oncology Drugs Introduction
11.1.4 Roche Revenue in Oncology Drugs Business (2017-2022)
11.1.5 Roche Recent Development
11.2 Celgene
11.2.1 Celgene Company Detail
11.2.2 Celgene Business Overview
11.2.3 Celgene Oncology Drugs Introduction
11.2.4 Celgene Revenue in Oncology Drugs Business (2017-2022)
11.2.5 Celgene Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Oncology Drugs Introduction
11.3.4 Novartis Revenue in Oncology Drugs Business (2017-2022)
11.3.5 Novartis Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Oncology Drugs Introduction
11.4.4 Bristol-Myers Squibb Revenue in Oncology Drugs Business (2017-2022)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Oncology Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Oncology Drugs Business (2017-2022)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck & Co.
11.6.1 Merck & Co. Company Detail
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Oncology Drugs Introduction
11.6.4 Merck & Co. Revenue in Oncology Drugs Business (2017-2022)
11.6.5 Merck & Co. Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Oncology Drugs Introduction
11.7.4 AstraZeneca Revenue in Oncology Drugs Business (2017-2022)
11.7.5 AstraZeneca Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Oncology Drugs Introduction
11.8.4 Pfizer Revenue in Oncology Drugs Business (2017-2022)
11.8.5 Pfizer Recent Development
11.9 Amgen
11.9.1 Amgen Company Detail
11.9.2 Amgen Business Overview
11.9.3 Amgen Oncology Drugs Introduction
11.9.4 Amgen Revenue in Oncology Drugs Business (2017-2022)
11.9.5 Amgen Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Detail
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Oncology Drugs Introduction
11.10.4 Eli Lilly Revenue in Oncology Drugs Business (2017-2022)
11.10.5 Eli Lilly Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Detail
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Oncology Drugs Introduction
11.11.4 AbbVie Revenue in Oncology Drugs Business (2017-2022)
11.11.5 AbbVie Recent Development
11.12 Takeda
11.12.1 Takeda Company Detail
11.12.2 Takeda Business Overview
11.12.3 Takeda Oncology Drugs Introduction
11.12.4 Takeda Revenue in Oncology Drugs Business (2017-2022)
11.12.5 Takeda Recent Development
11.13 Astellas
11.13.1 Astellas Company Detail
11.13.2 Astellas Business Overview
11.13.3 Astellas Oncology Drugs Introduction
11.13.4 Astellas Revenue in Oncology Drugs Business (2017-2022)
11.13.5 Astellas Recent Development
11.14 Ipsen
11.14.1 Ipsen Company Detail
11.14.2 Ipsen Business Overview
11.14.3 Ipsen Oncology Drugs Introduction
11.14.4 Ipsen Revenue in Oncology Drugs Business (2017-2022)
11.14.5 Ipsen Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Detail
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Oncology Drugs Introduction
11.15.4 Sanofi Revenue in Oncology Drugs Business (2017-2022)
11.15.5 Sanofi Recent Development
11.16 Bayer
11.16.1 Bayer Company Detail
11.16.2 Bayer Business Overview
11.16.3 Bayer Oncology Drugs Introduction
11.16.4 Bayer Revenue in Oncology Drugs Business (2017-2022)
11.16.5 Bayer Recent Development
11.17 Biogen Idec
11.17.1 Biogen Idec Company Detail
11.17.2 Biogen Idec Business Overview
11.17.3 Biogen Idec Oncology Drugs Introduction
11.17.4 Biogen Idec Revenue in Oncology Drugs Business (2017-2022)
11.17.5 Biogen Idec Recent Development
11.18 Teva
11.18.1 Teva Company Detail
11.18.2 Teva Business Overview
11.18.3 Teva Oncology Drugs Introduction
11.18.4 Teva Revenue in Oncology Drugs Business (2017-2022)
11.18.5 Teva Recent Development
11.19 Otsuka
11.19.1 Otsuka Company Detail
11.19.2 Otsuka Business Overview
11.19.3 Otsuka Oncology Drugs Introduction
11.19.4 Otsuka Revenue in Oncology Drugs Business (2017-2022)
11.19.5 Otsuka Recent Development
11.20 Eisai
11.20.1 Eisai Company Detail
11.20.2 Eisai Business Overview
11.20.3 Eisai Oncology Drugs Introduction
11.20.4 Eisai Revenue in Oncology Drugs Business (2017-2022)
11.20.5 Eisai Recent Development
11.21 Merck KGaA
11.21.1 Merck KGaA Company Detail
11.21.2 Merck KGaA Business Overview
11.21.3 Merck KGaA Oncology Drugs Introduction
11.21.4 Merck KGaA Revenue in Oncology Drugs Business (2017-2022)
11.21.5 Merck KGaA Recent Development
11.22 Gilead Sciences
11.22.1 Gilead Sciences Company Detail
11.22.2 Gilead Sciences Business Overview
11.22.3 Gilead Sciences Oncology Drugs Introduction
11.22.4 Gilead Sciences Revenue in Oncology Drugs Business (2017-2022)
11.22.5 Gilead Sciences Recent Development
13 REPORT CONCLUSION
14 DISCLAIMER
